CY1114975T1 - Σκευασμα εμφυτευματος παλιπεριδονης - Google Patents
Σκευασμα εμφυτευματος παλιπεριδονηςInfo
- Publication number
- CY1114975T1 CY1114975T1 CY20141100156T CY141100156T CY1114975T1 CY 1114975 T1 CY1114975 T1 CY 1114975T1 CY 20141100156 T CY20141100156 T CY 20141100156T CY 141100156 T CY141100156 T CY 141100156T CY 1114975 T1 CY1114975 T1 CY 1114975T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- weeks
- polyperidonic
- infection preparation
- rmakokinitika
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Μια ενδομυϊκά ενέσιμη σύνθεση βραδείας αποδέσμευσης κατάλληλη για τον επιτόπου σχηματισμό ενός στερεού εμφυτεύματος σε ένα σώμα, που περιλαμβάνει ένα φάρμακο, το οποίο είναι η παλιπεριδόνη και/ή τα φαρμακευτικά αποδεκτά άλατα της και συνδυασμοί αυτών, ένα βιοσυμβατό συμπολυμερές με βάση το γαλακτικό και το γλυκολικό οξύ με αναλογία μονομερών γαλακτικού προς το γλυκολικό οξύ της τάξης του 50:50 και διαλύτη DMSO, όπου η σύνθεση αποδεσμεύει το φάρμακο με άμεση έναρξη της δράσης του και συνεχώς για τουλάχιστον 8 εβδομάδες και όπου η σύνθεση έχει φαρμακοκινητικά χαρακτηριστικά in vivo κατάλληλα για τη χορήγηση του σκευάσματος ανά 8 εβδομάδες ή ακόμη μεγαλύτερες περιόδους.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170366.4A EP2529757B1 (en) | 2011-05-31 | 2012-05-31 | Paliperidone implant formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114975T1 true CY1114975T1 (el) | 2016-12-14 |
Family
ID=47074463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100156T CY1114975T1 (el) | 2012-05-31 | 2014-02-26 | Σκευασμα εμφυτευματος παλιπεριδονης |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP2529757B1 (el) |
| JP (1) | JP6430933B2 (el) |
| KR (1) | KR101892496B1 (el) |
| CN (2) | CN109966239A (el) |
| AU (1) | AU2013269546B2 (el) |
| BR (1) | BR112014029208B1 (el) |
| CA (1) | CA2874702C (el) |
| CL (1) | CL2014003215A1 (el) |
| CO (1) | CO7160109A2 (el) |
| CY (1) | CY1114975T1 (el) |
| DK (1) | DK2529757T3 (el) |
| EA (1) | EA029921B1 (el) |
| ES (1) | ES2456917T3 (el) |
| HR (1) | HRP20140158T1 (el) |
| IL (1) | IL235850A0 (el) |
| IN (1) | IN2014DN10673A (el) |
| MA (1) | MA37661B1 (el) |
| MX (1) | MX365097B (el) |
| MY (1) | MY181549A (el) |
| NZ (1) | NZ703319A (el) |
| PH (1) | PH12014502668A1 (el) |
| PL (1) | PL2529757T3 (el) |
| PT (1) | PT2529757E (el) |
| SG (1) | SG11201407971QA (el) |
| SI (1) | SI2529757T1 (el) |
| SM (1) | SMT201400044B (el) |
| UA (1) | UA115987C2 (el) |
| WO (1) | WO2013178811A1 (el) |
| ZA (1) | ZA201409297B (el) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2529756B1 (en) * | 2011-05-31 | 2021-05-19 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidone and/or Paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| HRP20211853T1 (hr) | 2010-05-31 | 2022-03-04 | Laboratorios Farmaceuticos Rovi, S.A. | Sastavi in situ injekcijskih biorazgradivih implantata |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| FI3744326T3 (fi) * | 2015-04-07 | 2024-02-02 | Janssen Pharmaceutica Nv | Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille |
| CN106038569A (zh) * | 2016-05-26 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种帕利哌酮植入剂及其制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| LT3506921T (lt) | 2016-08-31 | 2023-08-10 | Mapi Pharma Ltd | Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US11666573B2 (en) * | 2017-10-27 | 2023-06-06 | Geneora Pharma (Shijiazhuang) Co., Ltd. | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
| SG11202005949UA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
| AU2019275406B2 (en) | 2018-05-24 | 2024-11-14 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| IL303252A (en) | 2020-11-30 | 2023-07-01 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| KR102794804B1 (ko) | 2020-11-30 | 2025-04-10 | 얀센 파마슈티카 엔브이 | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 |
| EP4025187B1 (en) | 2020-11-30 | 2024-01-03 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
| US12472148B2 (en) | 2021-04-26 | 2025-11-18 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| EP4527389A1 (en) | 2022-05-18 | 2025-03-26 | Laboratorios Farmacéuticos Rovi S.A. | Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2915574C (en) * | 2003-07-18 | 2017-02-07 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| WO2006017537A1 (en) | 2004-08-04 | 2006-02-16 | Alza Corporation | Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| WO2008128436A1 (fr) | 2007-04-19 | 2008-10-30 | Youxin Li | Nouveaux composés pour le traitement de troubles psychotiques, procédés d'élaboration, et leurs utilisations |
| EP2152315B1 (en) * | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US20090036470A1 (en) | 2007-07-27 | 2009-02-05 | Jiri Bartl | Paliperidone derivatives |
| AU2008340101C1 (en) | 2007-12-19 | 2025-03-06 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2529756B1 (en) * | 2011-05-31 | 2021-05-19 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidone and/or Paliperidone implant formulation |
| HRP20211853T1 (hr) * | 2010-05-31 | 2022-03-04 | Laboratorios Farmaceuticos Rovi, S.A. | Sastavi in situ injekcijskih biorazgradivih implantata |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
-
2012
- 2012-05-31 EP EP12170366.4A patent/EP2529757B1/en active Active
- 2012-05-31 PL PL12170366T patent/PL2529757T3/pl unknown
- 2012-05-31 DK DK12170366.4T patent/DK2529757T3/en active
- 2012-05-31 PT PT121703664T patent/PT2529757E/pt unknown
- 2012-05-31 SI SI201230022T patent/SI2529757T1/sl unknown
- 2012-05-31 ES ES12170366.4T patent/ES2456917T3/es active Active
-
2013
- 2013-05-31 AU AU2013269546A patent/AU2013269546B2/en active Active
- 2013-05-31 BR BR112014029208A patent/BR112014029208B1/pt active IP Right Grant
- 2013-05-31 JP JP2015514532A patent/JP6430933B2/ja active Active
- 2013-05-31 MX MX2014014484A patent/MX365097B/es active IP Right Grant
- 2013-05-31 IN IN10673DEN2014 patent/IN2014DN10673A/en unknown
- 2013-05-31 CN CN201910004281.0A patent/CN109966239A/zh active Pending
- 2013-05-31 SG SG11201407971QA patent/SG11201407971QA/en unknown
- 2013-05-31 KR KR1020147036778A patent/KR101892496B1/ko active Active
- 2013-05-31 CN CN201380028041.5A patent/CN104349792A/zh active Pending
- 2013-05-31 EA EA201401348A patent/EA029921B1/ru unknown
- 2013-05-31 WO PCT/EP2013/061319 patent/WO2013178811A1/en not_active Ceased
- 2013-05-31 UA UAA201414185A patent/UA115987C2/uk unknown
- 2013-05-31 MY MYPI2014703550A patent/MY181549A/en unknown
- 2013-05-31 NZ NZ703319A patent/NZ703319A/en unknown
- 2013-05-31 CA CA2874702A patent/CA2874702C/en active Active
-
2014
- 2014-02-19 HR HRP20140158AT patent/HRP20140158T1/hr unknown
- 2014-02-26 CY CY20141100156T patent/CY1114975T1/el unknown
- 2014-04-03 SM SM201400044T patent/SMT201400044B/xx unknown
- 2014-11-23 IL IL235850A patent/IL235850A0/en active IP Right Grant
- 2014-11-26 CL CL2014003215A patent/CL2014003215A1/es unknown
- 2014-11-28 PH PH12014502668A patent/PH12014502668A1/en unknown
- 2014-12-16 MA MA37661A patent/MA37661B1/fr unknown
- 2014-12-17 ZA ZA2014/09297A patent/ZA201409297B/en unknown
- 2014-12-30 CO CO14285846A patent/CO7160109A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114975T1 (el) | Σκευασμα εμφυτευματος παλιπεριδονης | |
| CY1124369T1 (el) | Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης | |
| CY1124783T1 (el) | Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα | |
| CY1122252T1 (el) | Ενεσιμο παρασκευασμα | |
| CY1117719T1 (el) | Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2 | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CY1117964T1 (el) | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας | |
| CL2023002345A1 (es) | Composiciones y métodos para fabricar microparticulas de proteína. | |
| UA111162C2 (uk) | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю | |
| CY1119113T1 (el) | Σκευασματα με βαση το υαλουρονικο οξυ | |
| CY1125157T1 (el) | Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| CY1124782T1 (el) | Φαρμακοτεχνικες μορφες μακρας δρασης | |
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| CY1123583T1 (el) | Ανοσογονος συνθεση για χρηση στη θεραπεια | |
| SA517381298B1 (ar) | تركيبة صيدلية بثبات محسن | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| ECSP12011992A (es) | Formulación de liberación sostenida | |
| EA201790089A1 (ru) | Фармацевтические средства для лечения головокружения различной этиологии | |
| CY1114806T1 (el) | Βενζιμιδαζολες και φαρμακευτικες συνθεσεις αυτων | |
| TH159015A (th) | ริสเพอริโดนหรือสูตรตำรับในการปลูกถ่ายพาลิเพอริโดน | |
| EA201401007A1 (ru) | КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ НАЛТРЕКСОН, ДЛЯ ОБРАЗОВАНИЯ ИМПЛАНТОВ in situ | |
| TH159014A (th) | สูตรตำรับสิ่งปลูกถ่ายพาลิเพอริโด |